• Mutation; HGNC; HGNC:6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line).
  

PubMed=25080943; DOI=10.1038/srep05924; PMCID=PMC4118152
Yukinari Kato, Mika Kato Kaneko;
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
Sci. Rep. 4:5924.1-5924.9(2014)

PubMed=26492619; DOI=10.1089/mab.2015.0018
Satoshi Ogasawara, Hiroharu Oki, Mika Kato Kaneko, Yasukazu Hozumi, Xing Liu, Ryusuke Honma, Yuki Fujii, Takuro Nakamura, Kaoru Goto, Michiaki Takagi, Yukinari Kato;
Development of monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 34:318-326(2015)

PubMed=26937552; DOI=10.1089/mab.2015.0077
Yukinari Kato, Satoshi Ogasawara, Hiroharu Oki, Ryusuke Honma, Michiaki Takagi, Yuki Fujii, Takuro Nakamura, Noriko Saidoh, Hazuki Kanno, Mitsuo Umetsu, Satoshi Kamata ...Show all 18 authors... , Hiroshi Kubo, Mitsuhiro Yamada, Yoshihiko Sawa, Kei-ichi Morita, Hiroyuki Harada, Hiroyoshi Suzuki, Mika Kato Kaneko; Show fewer authors
Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:109-116(2016)

PubMed=27031228; DOI=10.1371/journal.pone.0152912; PMCID=PMC4816300
Yukinari Kato, Satoshi Ogasawara, Hiroharu Oki, Polina Goichberg, Ryusuke Honma, Yuki Fujii, Mika Kato Kaneko;
LpMab-12 established by CasMab technology specifically detects sialylated O-glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin.
PLoS ONE 11:e0152912.1-e0152912.13(2016)

PubMed=27328060; DOI=10.1089/mab.2016.0006
Satoshi Ogasawara, Mika Kato Kaneko, Ryusuke Honma, Hiroharu Oki, Yuki Fujii, Michiaki Takagi, Hiroyoshi Suzuki, Yukinari Kato;
Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:155-162(2016)

PubMed=27564251; DOI=10.1089/mab.2016.0031
Satoshi Ogasawara, Mika Kato Kaneko, Yukinari Kato;
LpMab-19 recognizes sialylated O-Glycan on Thr76 of human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:245-253(2016)

PubMed=28101903; DOI=10.1002/cam4.954; PMCID=PMC5313638
Mika Kato Kaneko, Takuro Nakamura, Ryusuke Honma, Satoshi Ogasawara, Yuki Fujii, Shinji Abe, Michiaki Takagi, Hiroyuki Harada, Hiroyoshi Suzuki, Yasuhiko Nishioka, Yukinari Kato;
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
Cancer Med. 6:382-396(2017)

PubMed=28387591; DOI=10.1089/mab.2017.0001
Shinji Yamada, Satoshi Ogasawara, Mika Kato Kaneko, Yukinari Kato;
LpMab-23: a cancer-specific monoclonal antibody against human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 36:72-76(2017)

Patent=US10227407
Yukinari Kato, Mika Kato Kaneko;
Anti-podoplanin antibody.
Patent number US10227407, 12-Mar-2019